Personalized lifestyle program for heart and metabolic health in adults with obesity
Tests a personalized lifestyle program in Emirati adults with obesity.
Key facts
- Who runs it
- Institute for Healthier Living Abu Dhabi
- Where
- Abu Dhabi, United Arab EmiratesSee the site
- Trial code
- Registry title
- Precision Lifestyle Medicine Program for IFHAS Participants
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 3 Aug 2026
- Expected to end
- 13 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Precision Lifestyle Medicine Program
- Standard IFHAS Care
- Record updated
- 3 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Emirati adults aged 25 to 50 with obesity (BMI 30-35 kg/m²) who live in Abu Dhabi and took part in IFHAS screening. It tests an 18-week personalised lifestyle program.
- Age
- 25 to 50 years
- Sex
- Men and women can join.
- Disease stage
- Obesity with a BMI of 30-35 kg/m².
- Earlier treatment
- Must not have taken weight-loss medicines (for example Ozempic, Saxenda, Wegovy) within 3 months before enrolment. Must have taken part in IFHAS screening before.
Main reasons for not taking part
- Taking weight-loss medicine such as GLP-1 drugs
- Pregnancy
- Transplant surgery within 12 months, or any surgery within 3 months before recruitment
- Active treatment for serious conditions such as cancer
- Cannot have an MRI or DEXA scan, or cannot take part in exercise
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Emiratis residing in Abu Dhabi emirate
- Aged 25-50 years
- BMI 30-35 kg/m²
- Thiqa cardholder
- Previous participation in IFHAS screening
- Able to provide informed consent
- Participant in the Emirati Genome Programme
- No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment
Who cannot take part
- Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy)
- Transplant surgery within 12 months
- Surgery within 3 months prior to recruitment
- Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation)
- Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation
- Aged under 25 years or over 50 years of age
- BMI range under 30 kg/m2 and over 35 kg/m2
- Pregnancy
- Physical limitations preventing exercise participation
- Current enrolment in other lifestyle intervention programs
- Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 50 years old?
Where in United Arab Emirates
- Institute for Healthier LivingAbu Dhabi, United Arab EmiratesContact: Shamma Al JneibiTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are:
Read full original descriptionShow less
* Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population?
Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health.
Participants will:
* Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.
The 2 groups in the trial
- Precision Lifestyle Medicine InterventionTreatment being tested
Participants receive an 18-week precision lifestyle medicine intervention program based on IFHAS screening and risk stratification, including personalized lifestyle recommendations and clinical follow-up. Participants remain in the study for 24 weeks, with cardiometabolic outcomes assessed before and after the intervention.
Treatment: Precision Lifestyle Medicine Program
- Standard IFHAS Care (Matched Control)Existing treatment, for comparison
Retrospective propensity score-matched control participants identified from the IFHAS cohort who receive standard IFHAS care and do not participate in the precision lifestyle medicine intervention. This comparison group is created using propensity score weighting to estimate intervention effects.
Treatment: Standard IFHAS Care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Application of a Precision Lifestyle Medicine Clinical Program for a Sample of IFHAS Screening Cohort
- Plain-language title
- Personalized lifestyle program for heart and metabolic health in adults with obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07742917, who can take part
- Record updated
- 3 August 2026